The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).
 
Stephen Opat
Honoraria - Abbvie; Celgene; Gilead Sciences; Janssen; Merck; Mundipharma; Roche; Takeda
Consulting or Advisory Role - Abbvie; Celgene; Gilead Sciences; Janssen; Merck; Mundipharma; Roche; Takeda
Research Funding - Abbvie; BeiGene; Epizyme; Gilead Sciences; Janssen; Merck; Roche; Takeda
 
Robert Marcus
Honoraria - Genentech; Roche
Consulting or Advisory Role - Gilead Sciences
Speakers' Bureau - Roche
Expert Testimony - Gilead Sciences
Travel, Accommodations, Expenses - Roche; Takeda
 
Craig Anthony Portell
Consulting or Advisory Role - Genentech/Roche; Pharmaceutical Research Associates; Pharmacyclics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
William Reed
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Melannie Co
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene; Pharmacyclics
Travel, Accommodations, Expenses - BeiGene; Pharmacyclics
 
Jane Huang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Judith Trotman
Research Funding - Beigene (Inst); celgene (Inst); Janssen-Cilag (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Takeda (Inst)